The Department of Commerce yesterday released notices announcing national security investigations on imports of pharmaceuticals, pharmaceutical ingredients and semiconductors. The investigations are being conducted under Section 232 of the Trade Expansion Act of 1962, which authorizes the President to impose tariffs or other trade restrictions if an investigation determines that importation of particular goods affect national security. Those goods have received exemptions from tariffs on imported goods that began April 5. The agency will accept comments on domestic production, the role of foreign supply chains, the impacts of trade policy and other information related to pharmaceutical and semiconductor imports for 21 days following publication in the April 16 Federal Register. 

Related News Articles

Headline
The Department of Health and Human Services and Drug Enforcement Administration Dec. 30 released a temporary rule extending for the fourth time waiver…
Headline
The Centers for Medicare & Medicaid Services Dec. 23 introduced a new drug pricing model for Medicare Part D and Medicaid beneficiaries. The Better…
Headline
The Centers for Medicare & Medicaid Services Dec. 19 issued two proposed rules for implementing alternative drug pricing models. The first proposed…
Headline
The White House announced Dec. 19 that it reached most-favored-nation deals with nine pharmaceutical companies, aligning their drug prices with the lowest paid…
Headline
An AHA blog examines new data released by the Health Resources and Services Administration on the growth of the 340B Drug Pricing Program.  “When…
Headline
The Trump administration announced a trade agreement with the U.K. Dec. 1 on pharmaceuticals that exempts U.K. drug products from Section 232 tariffs. In…